Want to see JP:7776 full AI Analyst Report?
7776 Stock Chart & Stats
¥259.00
-¥7.00(-1.73%)
At close: 4:00 PM EST
¥259.00
-¥7.00(-1.73%)
Day’s Range― - ―
52-Week Range¥201.00 - ¥518.00
Previous CloseN/A
Volume900.50K
Average Volume (3M)621.90K
Market Cap
¥8.46B
Enterprise Value¥7.80B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.24
Shares Outstanding39,160,420
10 Day Avg. Volume981,780
30 Day Avg. Volume621,903
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)7.08
Price to Sales (P/S)107.39
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Healthy Gross MarginsSustained gross margins near 48%–69% indicate strong underlying unit economics for CellSeed's products and services. Over a multi-month horizon this supports potential scalability: if revenue stabilizes, margins can protect operating leverage and make progress toward profitability more attainable.
Conservative LeverageLow debt-to-equity and modest total debt provide structural financial flexibility. This reduces near-term solvency risk and preserves capacity to raise capital or fund R&D without heavy interest burdens, an important foundation for a cash-burning biotech over the coming months.
Niche Regenerative-medicine FocusA specialized focus on cell sheet engineering and regenerative therapies is a durable competitive position: proprietary know-how, tailored manufacturing and service offerings create barriers to entry and multiple commercialization pathways beyond single product launches.
Bears Say
Sharp Revenue DeclineA more than 50% revenue drop in 2025 materially weakens the business's ability to cover fixed costs and invest in R&D. Over 2–6 months this heightens execution risk, constrains incremental scale benefits from healthy gross margins, and raises uncertainty about sustainable commercial traction.
Persistent Cash BurnConsistent negative operating and free cash flow indicates the company cannot self-fund operations or development under current revenue levels. This structural cash burn increases reliance on external financing, creating dilution risk and potential constraints on program continuity over the medium term.
Large Losses & Equity ErosionVery large operating and net losses, combined with declining shareholder equity and negative ROE, signal erosion of capital base. Persisting deficits impair financial resilience, raise funding needs, and make it harder to attract partners or investors crucial for long-term development and commercialization.
CellSeed Inc. News
7776 FAQ
What was CellSeed Inc.’s price range in the past 12 months?
CellSeed Inc. lowest stock price was ¥201.00 and its highest was ¥518.00 in the past 12 months.
What is CellSeed Inc.’s market cap?
CellSeed Inc.’s market cap is ¥8.46B.
When is CellSeed Inc.’s upcoming earnings report date?
CellSeed Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 47 days.
How were CellSeed Inc.’s earnings last quarter?
CellSeed Inc. released its earnings results on May 13, 2026. The company reported -¥7.24 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.24.
Is CellSeed Inc. overvalued?
According to Wall Street analysts CellSeed Inc.’s price is currently Overvalued.
Does CellSeed Inc. pay dividends?
CellSeed Inc. does not currently pay dividends.
What is CellSeed Inc.’s EPS estimate?
CellSeed Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSeed Inc. have?
CellSeed Inc. has 39,160,420 shares outstanding.
What happened to CellSeed Inc.’s price movement after its last earnings report?
CellSeed Inc. reported an EPS of -¥7.24 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.916%.
Which hedge fund is a major shareholder of CellSeed Inc.?
Currently, no hedge funds are holding shares in JP:7776
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSeed Inc.
CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass epithelial cell sheets for repairing the esophagus, as well as both regenerated cartilage sheets and chondrocyte sheets aimed at addressing knee osteoarthritis. Beyond its therapeutic pipeline, CellSeed manufactures and distributes a range of specialized cell cultureware. This includes UpCell, a temperature-responsive cultureware vital for cell-sheet engineering; RepCell, another temperature-sensitive product designed for efficient cell collection; and HydroCell, distinguished by its low cell-binding properties. The firm also provides supporting equipment, such as ThermoPlate III, a heating element constructed from transparent glass, and cellZscope, an automated system for real-time cell monitoring. Additionally, CellSeed offers contract development and manufacturing services. Founded in 2001, the company's main operations are situated in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
StemCell Institute
―
Japan Tissue Engineering Co., Ltd.
―